Walt is the father of two and spends his days playing with is kids, teaching them about the world, and having fun watching them grow up. Walt is also passionate about making a difference for patients. He spends his days focused on genetics and genomics and the insights they bring into disease biology. Walt works where science meets business and strategy, enabling insights from the lab to become the next generation of medicines that can change lives. He is enthusiastic about launching companies with emphatic, truly patient-centric cultures that effectively and efficiently execute drug discovery. He places priority on taking the time to listen to the patients whom we endeavor to help, recognizing that the value we aim to create is defined by the magnitude of the difference we can make in their lives.
Brett S. Abrahams
Brett S. Abrahams, Ph.D. is the Executive Vice President of Research & Development at Magnolia Neurosciences Corporation, a biotech start-up developing neuroprotective therapeutics for neurodegenerative disorders. Before joining Magnolia, Dr. Abrahams was Senior Director and Head, Pre-Clinical Biology at Ovid Therapeutics, Inc. (NASDAQ: OVID), a company developing new treatments for rare forms of autism and epilepsy. Prior to joining Ovid, Dr. Abrahams was a member of the faculty at the Albert Einstein College of Medicine, where he retains an adjunct appointment. His lab used genomic strategies to identify genes that increase risk for neurocognitive disorders and study these in model systems and patients. Results from his scientific research have been widely disseminated through publication of high impact peer reviewed manuscripts (e.g. New England Journal of Medicine, Cell, Nature, and Science Translational Medicine) and coverage in the popular press (e.g. ABC News, BBC News, Reuters, The Telegraph, and Time Magazine).
Dr. Mark Bear is a Picower Professor of Neuroscience at the Massachusetts Institute of Technology, Picower Institute for Learning and Memory, and a past Investigator of the Howard Hughes Medical Institute. Dr. Bear served as Director of The Picower Institute from 2007 to 2009. Prior to moving to MIT in 2003, Dr. Bear was on the faculty of Brown University School of Medicine for 17 years. After receiving his B.S. degree from Duke University, he earned his Ph.D. degree in neurobiology at Brown. He took postdoctoral training from Wolf Singer at the Max Planck Institute for Brain Research in Frankfurt, Germany, and from Leon Cooper at Brown. Bear’s laboratory has substantially advanced knowledge of how cerebral cortex is modified by experience. Dr. Bear has made fundamental discoveries on bidirectional synaptic plasticity, metaplasticity, the molecular basis of amblyopia (a cause of visual disability in children), and the pathophysiology of fragile X syndrome (the most common inherited cause of intellectual disability and autism). Dr. Bear has won multiple awards that include the United States Office of Naval Research Young Investigator Award, The Society for Neuroscience Young Investigator Award, the Brown University Class of 2000 Barrett Hazeltine Citation for Teaching Excellence, the William and Enid Rosen Award for Outstanding Contributions to Understanding Fragile X Syndrome, National Fragile X Foundation Pioneer Award, and the Ray Fuller Award, American Society for Pharmacology and Experimental Therapeutics. Dr. Bear been at the forefront of the efforts to translate knowledge of synaptic plasticity into new treatments for autism and amblyopia.
Jamil M. Beg
Jamil M. Beg joined 5AM Ventures in 2017 as a Principal and was promoted to Partner in 2020. Prior to 5AM, Mr. Beg was at Sage Therapeutics (NASDAQ: SAGE) where he contributed to building the company through business development, corporate strategy, medical affairs, health economics & outcomes research and commercialization roles. Previously, Mr. Beg was an investment professional at Quaker Partners and contributed to investments in the firm’s portfolio companies including EKR Therapeutics (acquired by Cornerstone Therapeutics), Transave Inhalation Therapeutics (acquired by Insmed), NuPathe (NASDAQ: PATH, acquired by Teva) and Cempra (NASDAQ: CEMP). Mr. Beg started his career at Cambridge Pharma Consultancy (acquired by IMS Health) with a focus on pricing, market access and health economics outcomes research strategies for the biopharma industry. Mr. Beg earned his B.S.E. in Bioengineering and Master of Biotechnology degrees from the University of Pennsylvania. He earned his M.B.A. in Healthcare Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania where he was a recipient of the Henry J. Kaiser Family Foundation Merit Award.
Federico received his Medical Doctor (MD) degree from the National University of La Plata in Argentina, as well as a PhD from the same institution. He has 20 years of experience in translational neuroscience and drug development in Academic, Hospital, Biotechnology, and Pharmaceutical Industry settings. He has worked at the Molecular Medicine Unit, School of Medicine, University of Manchester, UK; the University of New Mexico School of Medicine, USA as Research Assistant Professor; and at the Department of Neurosurgery in the Methodist Hospital at the Texas Medical Center in Houston, USA. In 2009 he moved to Basel, Switzerland to lead the Novartis Safety Genomic group at the Novartis Institutes of Biomedical Research (NIBR) where he led a global group of MDs and PhDs involved in translational drug development. In 2013 he joined the Neuroscience Disease Area at Roche where he led clinical programs developing new drugs for Neurodevelopmental Disorders, especially Autism Spectrum Disorder (ASD). Since 2018 he has been working in the biotechnology sector developing drugs for Rare Diseases. He currently serves as Vice President and head of Clinical Science at VectivBio in Basel, Switzerland. He has an extensive publication record, including original investigations, review papers, book chapters, and meeting presentations.